Edition:
United States

Vivus Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

3.21USD
16 Nov 2018
Change (% chg)

-- (--)
Prev Close
$3.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
14,650
52-wk High
$9.88
52-wk Low
$3.18

Latest Key Developments (Source: Significant Developments)

Vivus Reports Qtrly ‍loss Per Share $0.10​
Tuesday, 13 Mar 2018 04:05pm EDT 

March 13 (Reuters) - Vivus Inc ::VIVUS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS.VIVUS INC QTRLY ‍LOSS PER SHARE $0.10​.VIVUS INC QTRLY ‍TOTAL REVENUE OF $11.9 MILLION VERSUS $81.8 MILLION.  Full Article

Vivus Announces Change In Leadership
Tuesday, 26 Dec 2017 04:05pm EST 

Dec 26 (Reuters) - Vivus Inc ::VIVUS ANNOUNCES CHANGE IN LEADERSHIP.VIVUS INC - BOARD MEMBER THOMAS B. KING APPOINTED INTERIM CEO.VIVUS INC - SETH FISCHER STEPS DOWN AS CEO EFFECTIVE DECEMBER 31, 2017.  Full Article

Vivus reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Vivus Inc :Vivus reports third quarter 2017 financial results.Vivus Inc - ‍total revenue, net for third quarters of 2017 and 2016, was $15.2 million and $13.4 million, respectively​.Vivus Inc - qtrly ‍basic and diluted net loss per share $0.06​.  Full Article

VIVUS and Alvogen announce marketing agreement for Qsymia in the Republic of Korea
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Alvogen Korea Co Ltd <002250.KS>:VIVUS Inc - ‍Alvogen will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea​​.VIVUS Inc - ‍Alvogen will market Qsymia in Republic Of Korea for treatment of chronic weight management or weight-related conditions​.VIVUS Inc - ‍VIVUS will receive an upfront payment in addition to future milestone payments​.VIVUS Inc - ‍VIVUS will receive royalties on Alvogen's net sales of Qsymia​.  Full Article

Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation
Wednesday, 30 Aug 2017 04:05pm EDT 

Aug 30 (Reuters) - Vivus Inc ::Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation.Vivus Inc - ‍settlement permits Dr. Reddy's to begin selling a generic version of qsymia on June 1, 2025, or earlier under certain circumstances​.Vivus - ‍in event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of generic version of qsymia​.  Full Article

Vivus Q2 loss per share $0.13
Thursday, 3 Aug 2017 04:15pm EDT 

Aug 3 (Reuters) - Vivus Inc ::Vivus reports second quarter 2017 financial results.Qtrly loss per share $0.13; qtrly total revenue $11.2 million versus $13.8 million.  Full Article

Vivus reports Q1 loss per share $0.01
Wednesday, 3 May 2017 04:10pm EDT 

May 3 (Reuters) - Vivus Inc :Vivus reports 2017 first quarter financial results.Total revenue, net for first quarters of 2017 and 2016, was $27.0 million and $15.3 million, respectively.Q1 loss per share $0.01.  Full Article

Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi
Monday, 27 Mar 2017 08:30am EDT 

Vivus Inc : Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi . Says Sanofi will provide transition services to avoid adverse impacts to regulatory approval applications in process .Agreement with Sanofi to return commercial rights for Stendra in Africa, Middle East, Turkey, Commonwealth Of Independent States, including Russia, to Co.  Full Article

Vivus qtrly earnings per share $0.54
Wednesday, 8 Mar 2017 04:10pm EST 

Vivus Inc : Vivus reports fourth quarter and full year 2016 financial results . Vivus Inc - qtrly earnings per share $0.54 . Vivus Inc - total revenue, net for quarter was $81.8 million compared to $15.3 million . Vivus - about 100,000 qsymia prescriptions were dispensed in quarter , compared to 132,000 in same period in 2015 .Vivus Inc says in Q4 of 2016, recognized a one-time up-front license fee of $69.4 million.  Full Article

Vivus entered into settlement agreement with Hetero on Jan. 3
Monday, 9 Jan 2017 04:16pm EST 

Vivus Inc : On Jan 3, co entered into a settlement agreement with hetero - sec filing . Vivus- Settlement resolves co's lawsuit in response to Hetero's filing of ANDA, seeking to market generic versions of Stendra before expiration of asserted patents . Vivus - under settlement agreement, hetero was granted license to manufacture, commercialize generic version of stendra described in its ANDA filing in U.S. .Vivus - settlement agreement provides for full settlement of all claims asserted in suit, subject to court's acceptance of stipulation of dismissal.  Full Article